Latest Advanced Prostate Cancer News2017-10-19T10:43:14-04:00

Efficacy and Safety of Enzalutamide (Xtandi) Monotherapy in Hormone-Naive Prostate Cancer (HNPC)

Xtandi is often referred to as a “super bicalutamide (Casodex).” Casodex functions as a androgen blockade, which deters testosterone from being able to interact with the prostate cancer cell and feed the growth of the [...]

Sorting Out the Recent Negative News about the Role of Omega 3 Fatty Acids in the Diet & Its Relationship to Prostate Cancer

The recent news is unavoidable, Omega-3 Fatty Acids, usually used by men with heart ailments and prostate cancer is tied to a 71% increase of developing prostate cancer and that the cancer is often an [...]

Salvage Radio Therapy Extends Life Without Regard to PSA Doubling Time

Researchers at Duke University observed a survival benefit for men who had salvage radiation therapy (RT) for prostate-specific antigen (PSA) failure after radical prostatectomy (RP) in the men who experience a rapid rises in PSA [...]

Increasing Cost of Treating Men with Advanced Prostate Cancer & Its Effects on the Payers

The treatment of advanced prostate cancer, and in particular castrate resistant prostate cancer (CRPC), has changed greatly over the last 4 years. Treatment options have expanded and now offer multiple treatment possibilities that did not [...]

XTANDI (Enzalutamide) Has Been Authorized in the European Union (EU) for Advanced Prostate Cancer

The great news for for our brothers in Europe is that Xtandi (Enzalutamide) has been approved for use in the European Union (EU) for the treatment of men with metastatic castration-resistant prostate cancer whose disease [...]

Go to Top